---
title: "Onco-Innovations (ONCO) news: reverse split and delisting"
url: "https://aibio.space/companies/onco-innovations/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ONCO reverse split, delisting, offering, convertible notes, Nasdaq notice and merger news: Onconetix sets a 1-for-10 reverse stock split for November 6."
---

ONCO Onco-Innovations Ltd. NEO · Canada

# Onco-Innovations (ONCO) news ONCO reverse split, delisting and offering news

Listings · 2026-10-26

## [Onconetix sets a 1-for-10 reverse stock split for November 6](https://aibio.space/news/onconetix-sets-1-10-reverse-stock-split-november-6/)

The split cuts the share count to about 588,677 from roughly 5,886,774. The stock keeps trading on Nasdaq as ONCO under a new CUSIP.

## Latest Onco-Innovations news

1. 2026-09-14 Company Updates [Onconetix provides $2.5 million bridge advance to Realbotix before acquisition](https://aibio.space/news/onconetix-provides-2-5-million-bridge-advance-realbotix-before/) The bridge facility provides up to $5,000,000 to Realbotix LLC, the target of a pending all-stock share exchange, with an initial advance of $2,500,000.
2. 2026-07-28 Financings [Onconetix sells $30,249,600 of Series F preferred in PIPE financing](https://aibio.space/news/onconetix-sells-30-249-600-series-f-preferred-pipe-financing/) The securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.
3. 2026-05-19 Listings [Onconetix to effect 1-for-10 reverse stock split on May 21, 2026](https://aibio.space/news/onconetix-effect-1-10-reverse-stock-split-may-21-2026/) The Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.
4. 2026-05-13 Company Updates [Onconetix reports Q1 2026 progress at Proteomedix](https://aibio.space/news/onconetix-reports-q1-2026-progress-proteomedix/) The Swiss unit added two peer-reviewed papers, began enrolling in a U.S. validation study with Labcorp and kept expanding sales in Europe. The release does not report quarterly revenue or cash.
5. 2026-04-24 Company Updates [Onconetix directors Oakley and Meier resign; Dorf named chairman](https://aibio.space/news/onconetix-directors-oakley-meier-resign-dorf-named-chairman/) Josh Epstein joined the board on April 23, 2026 and chairs its Nominating and Corporate Governance Committee. The 8-K says neither resignation involved a disagreement with management.
6. 2025-10-03 Financings [Onconetix sells convertible preferred and warrants for approximately $6.25 million](https://aibio.space/news/onconetix-sells-convertible-preferred-warrants-approximately-6-25/) Institutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.
7. 2025-07-16 Mergers [Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%](https://aibio.space/news/onconetix-signs-merger-deal-ocuvex-ocuvex-holders-would-own-90-percent/) Onconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.
8. 2025-05-22 Listings [Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone](https://aibio.space/news/onconetix-gets-nasdaq-notice-unfiled-10-q-issues-294-117-65-note/) Nasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.
9. 2025-04-01 Distress [Onconetix files NT 10-K late filing notice, says cash fell to $0.6 million at year end](https://aibio.space/news/onconetix-files-nt-10-k-late-filing-notice-says-cash-fell-0-6-million/) Onconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.
10. 2025-04-01 Distress [Onconetix delays 10-K as cash falls to $0.6 million at year end](https://aibio.space/news/onconetix-delays-10-k-cash-falls-0-6-million-year-end/) The company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.

## Onco-Innovations at a glance

- **Ticker**: ONCO

- **Listing**: NEO

- **Country**: Canada

- **Cash, Jun 30, 2026**: $5.9 million

### Related companies

- [NanoSphere Health Sciences](https://aibio.space/companies/nanosphere-health-sciences/) CSE: NSHS.X
- [Vaxil Bio](https://aibio.space/companies/vaxil-bio/) TSXV: VXL
- [Eupraxia Pharmaceuticals](https://aibio.space/companies/eupraxia-pharmaceuticals/) TSX: EPRX
- [ProMIS Neurosciences](https://aibio.space/companies/promis-neurosciences/) NASDAQ: PMN
- [AbCellera Biologics](https://aibio.space/companies/abcellera-biologics/) NASDAQ: ABCL
- [ME Therapeutics Holdings](https://aibio.space/companies/me-therapeutics/) CSE: METX
- [Sernova Biotherapeutics](https://aibio.space/companies/sernova-biotherapeutics/) TSX: SVA
- [BriaCell Therapeutics](https://aibio.space/companies/briacell-therapeutics/) TSX: BCT

### Also on NEO

- [Helus Pharma](https://aibio.space/companies/helus-pharma/) HELP

## What Onco-Innovations does

Onconetix, Inc. describes itself as a commercial stage biotechnology company focused on men's health and oncology. Its main product is Proclarix, a protein-based blood test for prostate cancer that uses the same sample as a regular PSA test. Proclarix helps doctors and patients with unclear PSA results decide whether a biopsy is needed. It is approved for sale in the European Union under the In Vitro Diagnostic Regulation, and the company expects to market it in the United States as a lab developed test through its license agreement with LabCorp. Onconetix acquired ENTADFI, an FDA-approved once-daily pill for BPH, in April 2023, but abandoned its commercialization and no longer holds inventory of the product. The company relies on third-party manufacturers, with single-source suppliers for commercial product. As of December 31, 2025, it reported cash of approximately $5.2 million, and the filing states that substantial doubt exists about its ability to continue as a going concern. In February 2026 it entered into a share exchange agreement with Realbotix Corp.

| Product or program | What it is | Stage |
|---|---|---|
| Proclarix | Blood test to help diagnose prostate cancer in patients with unclear PSA results | Approved for sale in the European Union |
| ENTADFI | Once-daily finasteride and tadalafil pill for BPH | FDA-approved; commercialization abandoned |

Summarised from the company's [10-K filed Mar 13, 2026](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/ea0280547-10k_onconetix.htm).

## Onco-Innovations annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$815,371](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/) | [$2.5 million](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/) |
| Research and development |  | [$154,359](https://www.sec.gov/Archives/edgar/data/1782107/000121390025049687/) |
| Net income (loss) | [-$14.0 million](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/) | [-$58.7 million](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/) |
| Cash from operations | [-$9.7 million](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/) | [-$10.5 million](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/) |
| Cash and equivalents | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1782107/000121390026089093/) | [$646,500](https://www.sec.gov/Archives/edgar/data/1782107/000121390026089093/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Onco-Innovations

Did Onco-Innovations do a reverse stock split?

Our latest story on this, dated Oct 26, 2026: "Onconetix sets a 1-for-10 reverse stock split for November 6". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onconetix-sets-1-10-reverse-stock-split-november-6/).

Was Onco-Innovations delisted?

Our latest story on this, dated May 22, 2025: "Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onconetix-gets-nasdaq-notice-unfiled-10-q-issues-294-117-65-note/).

Has Onco-Innovations raised money recently?

Our latest story on this, dated Jul 28, 2026: "Onconetix sells $30,249,600 of Series F preferred in PIPE financing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onconetix-sells-30-249-600-series-f-preferred-pipe-financing/).

Has Onco-Innovations sold convertible notes?

Our latest story on this, dated Jul 28, 2026: "Onconetix sells $30,249,600 of Series F preferred in PIPE financing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onconetix-sells-30-249-600-series-f-preferred-pipe-financing/).

Has Onco-Innovations received a Nasdaq deficiency notice?

Our latest story on this, dated May 22, 2025: "Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onconetix-gets-nasdaq-notice-unfiled-10-q-issues-294-117-65-note/).

Is Onco-Innovations involved in a merger or acquisition?

Our latest story on this, dated Jul 16, 2025: "Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onconetix-signs-merger-deal-ocuvex-ocuvex-holders-would-own-90-percent/).

What is the ticker symbol of Onco-Innovations?

Onco-Innovations Ltd. trades under the ticker ONCO on NEO.

Where is Onco-Innovations listed?

Onco-Innovations Ltd. is listed on NEO. Our directory also records these other listings: GETTEX:W1H; LS:A3EKSZ; LSX:A3EKSZ; OTC:ONNVF.

Which country or territory is Onco-Innovations listed under?

Our directory records Onco-Innovations Ltd. under Canada.

What does Onco-Innovations do?

Our directory classifies Onco-Innovations Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Onco-Innovations?

The ISIN recorded for Onco-Innovations Ltd. is CA68237C1059.

Does aibio.space cover Onco-Innovations?

aibio.space lists Onco-Innovations Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

What does Onco-Innovations develop?

Onconetix, Inc. describes itself as a commercial stage biotechnology company focused on men's health and oncology. Its main product is Proclarix, a protein-based blood test for prostate cancer that uses the same sample as a regular PSA test.

What is Proclarix from Onco-Innovations?

Proclarix: Blood test to help diagnose prostate cancer in patients with unclear PSA results Stage: Approved for sale in the European Union.

What is ENTADFI from Onco-Innovations?

ENTADFI: Once-daily finasteride and tadalafil pill for BPH Stage: FDA-approved; commercialization abandoned.

## Investor discussion: Onco-Innovations

Members talk about Onco-Innovations (ONCO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Onco-Innovations, newest first. Each line links the filing it comes from.

1. 2026-10-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026112527/ea030972301ex99-1.htm)
2. 2026-10-23 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026111883/ea0309474-425_onconetix.htm)
3. 2026-10-07 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026107480/ea0307907-def14a_onconetix.htm)
4. 2026-09-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026100837/ea0305710-pre14a_onconetix.htm)
5. 2026-07-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026082879/ea0299510-8k_onconetix.htm)
6. 2026-06-24 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026071316/ea029568502-425_onconetix.htm)
7. 2026-05-19 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026058997/ea029154301ex99-1.htm)
8. 2026-05-04 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/ea0288982-8k_onconetix.htm)
9. 2026-03-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026035976/ea0283690-def14a_onconetix.htm)
10. 2026-03-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026034902/ea028356901ex99-1.htm)
11. 2026-03-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026029263/ea0282130-pre14a_onconetix.htm)
12. 2026-03-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/ea0280547-10k_onconetix.htm)
13. 2026-02-12 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026015214/ea0276704-8k425_onconet.htm)
14. 2026-02-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026013724/ea0276183-8k_onconetix.htm)
15. 2026-01-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390026000080/ea0271503-def14a_onconetix.htm)
16. 2025-12-22 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025124575/ea0270513-pre14a_onconetix.htm)
17. 2025-11-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025108093/ea0264698-def14a_onconetix.htm)
18. 2025-10-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025103182/ea0262617-pre14a_onconetix.htm)
19. 2025-10-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025095847/ea0259860-8k_onconetix.htm)
20. 2025-09-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/ea025819601ex99-1_onconetix.htm)
21. 2025-07-16 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/ea024881501ex99-1_oncone.htm)
22. 2025-06-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025054501/ea024581801ex99-1_onconetix.htm)
23. 2025-06-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,2.03,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025053367/ea024538701ex99-1_onconetix.htm)
24. 2025-06-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025051573/ea0244883-8k_onconetix.htm)
25. 2025-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025046909/ea024328701ex99-1_onconetix.htm)
26. 2025-04-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025036959/ea0240055-def14a_onconetix.htm)
27. 2025-04-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025037765/ea024032601ex99-1_onconetix.htm)
28. 2025-04-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025033295/ea0238654-8k_oncon.htm)
29. 2025-04-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025033378/ea0238864-pre14a_onconetix.htm)
30. 2025-04-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/ea023747101ex99-1_oncon.htm)

## Listing details

Onco-Innovations Ltd. is a public biotech or pharmaceutical company listed on NEO under the ticker ONCO, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Onco-Innovations Ltd.

- **Ticker**: ONCO

- **Listing**: NEO

- **Country or territory**: Canada

- **Business scope**: Biotechnology

- **ISIN**: CA68237C1059

- **Other listed symbols**: GETTEX:W1H; LS:A3EKSZ; LSX:A3EKSZ; OTC:ONNVF

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NEO-ONCO/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/onco-innovations/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Onco-Innovations (ONCO) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/onco-innovations/